You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Liraglutide - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for liraglutide and what is the scope of patent protection?

Liraglutide is the generic ingredient in two branded drugs marketed by Novo and Novo Nordisk Inc, and is included in two NDAs. There are twenty patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Liraglutide has two hundred and three patent family members in twenty-nine countries.

There are seven drug master file entries for liraglutide. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for liraglutide
International Patents:203
US Patents:20
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: 7
Finished Product Suppliers / Packagers: 3
Clinical Trials: 424
Patent Applications: 7,047
Drug Prices: Drug price trends for liraglutide
What excipients (inactive ingredients) are in liraglutide?liraglutide excipients list
DailyMed Link:liraglutide at DailyMed
Drug Prices for liraglutide

See drug prices for liraglutide

Recent Clinical Trials for liraglutide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ChicagoEarly Phase 1
Mỹ Đức HospitalPhase 3
Columbia UniversityPhase 4

See all liraglutide clinical trials

Generic filers with tentative approvals for LIRAGLUTIDE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up18MG/3ML(6MG/ML)INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for liraglutide
Paragraph IV (Patent) Challenges for LIRAGLUTIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SAXENDA Injection liraglutide 18 mg/3 mL prefilled syringe 206321 1 2021-08-16
VICTOZA Injection liraglutide 18 mg/3 mL prefilled syringe 022341 1 2016-12-12

US Patents and Regulatory Information for liraglutide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Novo SAXENDA liraglutide SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Novo SAXENDA liraglutide SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for liraglutide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 ⤷  Sign Up ⤷  Sign Up
Novo SAXENDA liraglutide SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 ⤷  Sign Up ⤷  Sign Up
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for liraglutide

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2597103 2017/015 Ireland ⤷  Sign Up PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912
2209800 C300698 Netherlands ⤷  Sign Up PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
2209800 132014902311502 Italy ⤷  Sign Up PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.